VivoSim Labs, Inc. (NASDAQ:VIVS – Get Free Report) shares passed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $0.18 and traded as high as $0.32. VivoSim Labs shares last traded at $0.2915, with a volume of 790,857,365 shares trading hands.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VivoSim Labs in a research note on Tuesday. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.
Check Out Our Latest Stock Report on VIVS
VivoSim Labs Price Performance
The company has a market capitalization of $5.91 million, a P/E ratio of -0.08 and a beta of 1.58. The company has a fifty day moving average price of $0.18 and a 200 day moving average price of $0.95.
VivoSim Labs (NASDAQ:VIVS – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter. VivoSim Labs had a negative return on equity of 498.57% and a negative net margin of 7,605.93%. The company had revenue of $0.05 million during the quarter.
VivoSim Labs Company Profile
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds.
Read More
- Five stocks we like better than VivoSim Labs
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for VivoSim Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VivoSim Labs and related companies with MarketBeat.com's FREE daily email newsletter.
